Previous close | 30.17 |
Open | 28.70 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 28.70 - 28.70 |
52-week range | 22.54 - 38.65 |
Volume | |
Avg. volume | 83 |
Market cap | 12.82M |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | 0.22 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures. A live webcast with presentation slides will
Net sales of Qelbree® increased 75% to $45.1 million compared to first quarter 2023.Total revenues were $143.6 million. Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales (non-GAAP)(1) increased 12% to $100.7 million compared to first quarter 2023.Operating loss was $(3.2) million. Adjusted operating earnings (non-GAAP)(1) was $22.3 million.Reiterates full year 2024 financial guidance, including total revenue guidance of $580 million to $620 million, operating loss guidance
M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ('Supernus'), a biopharmaceutical company focused on the development and commercialization of products for the treatment of diseases of the central nervous system (CNS), to seek regulatory approval and commercialize Qelbree® (Viloxazine XR) under M8's trademark in Latin America.